Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A KEITH

Showing results (881-890 of 918) with videos related to

Pageof 92
Sort By:
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Proceedings. Biological Sciences|June 30, 2026
Three decades of classifying threatened species: lessons learned from and about the IUCN Red List criteria for quantifying extinction riskH Resit Akçakaya, E J Milner-Gulland, Mike Hoffmann, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
JAMA Oncology|October 30, 2020
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeN Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
Blood Cancer Discovery|June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFaith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Pageof 92

Showing results (881-890 of 918) with videos related to

Sort By:
Pageof 92
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Proceedings. Biological Sciences|June 30, 2026
Three decades of classifying threatened species: lessons learned from and about the IUCN Red List criteria for quantifying extinction riskH Resit Akçakaya, E J Milner-Gulland, Mike Hoffmann, et al.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
JAMA Oncology|October 30, 2020
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeN Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
Blood Cancer Discovery|June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFaith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Pageof 92